GVT
NKTR icon

Genesee Valley Trust’s Nektar Therapeutics NKTR Stock Holding History

Genesee Valley Trust’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$200K Sell
154
-137
-47% -$177K 0.08% 210
2017
Q4 		$261K Sell
291
-446
-61% -$264K 0.11% 165
2017
Q3 		$265K Sell
737
-8
-1% -$2.5K 0.11% 161
2017
Q2 		$219K Sell
745
-9
-1% -$2.6K 0.09% 202
2017
Q1 		$265 Sell
754
-7
-0.9% -$1.57K 0.18% 172
2016
Q4 		$140 Sell
761
-52
-6% -$10.6K 0.1% 221
2016
Q3 		$209K Buy
813
+4
+0.5% +$1.03K 0.13% 238
2016
Q2 		$173K Buy
809
+43
+6% +$9.61K 0.11% 229
2016
Q1 		$158K Sell
766
-95
-11% -$18.2K 0.11% 217
2015
Q4 		$218K Sell
861
-2
-0.2% -$411 0.14% 204
2015
Q3 		$142K Buy
863
+19
+2% +$3.36K 0.09% 229
2015
Q2 		$158K Sell
844
-18
-2% -$3.1K 0.1% 260
2015
Q1 		$142K Buy
862
+3
+0.3% +$617 0.09% 266
2014
Q4 		$200K Sell
859
-358
-29% -$76.5K 0.13% 258
2014
Q3 		$220K Buy
1,217
+14
+1% +$2.68K 0.14% 255
2014
Q2 		$231K Sell
1,203
-4
-0.3% -$707 0.14% 259
2014
Q1 		$219K Sell
1,207
-10
-0.8% -$1.98K 0.14% 253
2013
Q4 		$207K Buy
1,217
+6
+0.5% +$968 0.14% 272
2013
Q3 		$190K Sell
1,211
-10
-0.8% -$1.85K 0.14% 267
2013
Q2 		$212K Buy
+1,221
New +$187K 0.17% 246

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Genesee Valley Trust's NKTR Position: Q1 2018 in Review

Genesee Valley Trust reduced its Nektar Therapeutics (NKTR) stake by 47% in Q1 2018, selling an estimated $177K and leaving 154 shares worth $200K. The position accounts for 0.08% of the portfolio, ranked #210.

Genesee Valley Trust first reported a position in NKTR in Q2 2013 and has held it in 20 quarters since. The position peaked at $265K in Q3 2017. 358 funds tracked by Wall St. Rank hold NKTR as of Q1 2018.

  • Genesee Valley Trust held 154 shares of Nektar Therapeutics worth $200K as of Q1 2018.
  • Genesee Valley Trust sold 137 Nektar Therapeutics shares in Q1 2018, an estimated $177K.
  • Nektar Therapeutics made up 0.08% of Genesee Valley Trust's portfolio in Q1 2018, its #210 holding.
  • Genesee Valley Trust first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 20 quarters since.
  • Genesee Valley Trust's Nektar Therapeutics position peaked at $265K in Q3 2017.
  • 358 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2018.

Based on Genesee Valley Trust's 13F filing for Q1 2018, filed 3 Apr 2018.